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A B S T R A C T
Tuberculosis (TB) and human immunodeﬁciency virus (HIV) infection are leading causes of disease and
death in Vietnam, but TB/HIV disease trends and the proﬁle of co-infected patients are poorly described.
Methods: We examined national TB and HIV notiﬁcation data to provide a geographic overview and
describe relevant disease trends within Vietnam. We also compared the demographic and clinical
proﬁles of TB patients with and without HIV infection.
Results: During the past 10 years (2005–2014) cumulative HIV case numbers and deaths increased to
298,151 and 71,332 respectively, but access to antiretroviral therapy (ART) improved and new infections
and deaths declined. From 2011-2014 routine HIV testing of TB patients increased from 58.9% to 72.5%
and of all TB patients diagnosed with HIV in 2014, 2,803 (72.4%) received ART. The number of multidrug
resistant (MDR)-TB cases enrolled for treatment increased almost 3-fold (578 to 1,532) from 2011-2014.
The rate of HIV co-infection in MDR and non-MDR TB cases (51/1,532; 3.3% vs 3,774/100,555; 3.8%; OR
0.77, 95% CI 0.7–1.2) was similar in 2014.
Conclusions: The care of TB/HIV co-infected patients have shown sustained improvement in Vietnam.
Rising numbers of MDR-TB cases is a concern, but this is not ‘‘driven’’ by HIV co-infection.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Tuberculosis (TB) and human immunodeﬁciency virus (HIV)
infection present major global health challenges. Their mutually
detrimental effect has been well documented and is most evident in
Sub-Saharan Africa.1,2 Of all TB cases identiﬁed in 2014, 1.2 million
(12%) were co-infected with HIV and 0.4 million TB-related deaths
were reported in people living with HIV.3 Increasing rates of multi-
drug resistant (MDR)-TB and TB/HIV co-infection place a tremen-
dous strain on public health resources and complicate TB control
efforts.3 TB/HIV co-infection has not been considered a major driver
of the TB epidemic in the Asia-Paciﬁc region, but a slowly increasing
proportion of TB/HIV co-infected patients has been documented,
despite recent reductions in TB case numbers.4,5* Corresponding author at: Tuberculosis Laboratory, Vietnam National Institute
of Hygiene and Epidemiology, No 1 Yersin Street, Hai Ba Trung District, Hanoi,
10000, Vietnam. Tel.: +84 983110183.
E-mail address: qtri6675@uni.sydney.edu.au (Q.M. Trinh).
http://dx.doi.org/10.1016/j.ijid.2016.03.021
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).In 2014, Vietnam was one of the high TB burden countries within
the Asia-Paciﬁc region, ranking 11th among the 22 highest TB
burden countries in the world.3 TB is the second most common
infectious cause of death in Vietnam, after respiratory infections in
general, with 100,349 new and recurrent TB cases and 17,000 TB
deaths recorded in 2014.3 Vietnam has made signiﬁcant progress in
its TB control efforts, achieving Millennium Developmental Goal
(MDG) targets for reductions in TB incidence, prevalence and
mortality well before the 2015 target date.6 However, rising
numbers of MDR-TB patients is a major concern; Vietnam is ranked
14th among the 27 highest MDR-TB burden countries in the world.3
The ﬁrst case of HIV in Vietnam was detected in 1990.7 After an
initial delay in acknowledging and recognizing the full extent of the
problem, Vietnam has made signiﬁcant efforts to address the HIV/
AIDS epidemic. Worryingly the HIV prevalence among high-risk
populations remains high in several cities and provinces, with
increasing rates of HIVinfection among men who have sex withmen.8
In addition, Vietnam is witnessing a change in HIV transmission
patterns with increasing numbers of heterosexually transmitted HIVciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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(ART) and isoniazid preventive therapy (IPT) helped to reduce the
number of TB/HIV co-infected patients in Vietnam,11 but despite
the progress made TB and HIV remain leading causes of disease and
death. Data from the HIV and TB control programmes have never
been combined to provide a comprehensive overview of the
problem, assess disease trends and describe the proﬁle of TB/HIV
co-infected patients in Vietnam. In this report we examined
national TB and HIV notiﬁcation data to provide a geographic
overview and describe recent disease trends within Vietnam.
2. Methods
The cumulative number of HIV-infected cases, number of
patients on ART and IPT, as well as the number of newly diagnosed
HIV-infections and deaths over a 10-year period (2005-2014) were
reviewed using HIV program data. In addition, we analysed routine
notiﬁcation data collected by the national TB program in Vietnam
over a 4-year period (2011-2014). We assessed geographic
patterns of disease in 2014, by mapping the TB incidence, HIV
prevalence and total number of TB/HIV co-infected patients
notiﬁed in each province. We compared the proﬁles of TB patients
with and without HIV infection by combining more detailed HIV
and TB programmatic data from the 2011-2014 period. Descriptive
and comparative statistics was performed using Stata v.13 (Stata
Corporation, Texas, USA). Odds ratios and 95% conﬁdence intervals
(CI) were calculated using Chi2 test and StatCalc function in Epi
Info 7 (wwwn.cdc.gov/epiinfo/).
3. Results
TB notiﬁcation rates were highest in the Southern provinces of
Vietnam, especially in Ho Chi Minh City and the greater Mekong
River Delta where incidence rates exceeded 200/100,000 popula-
tion. TB rates were lowest in the Northern mountainous provinces
and central highland areas (<50/100,000 population). In contrast,
HIV prevalence rates were high in the Northern mountainous
provinces. The greatest absolute numbers of TB/HIV co-infected
patients were identiﬁed in and around the two biggest metropoli-
tan areas (Ho Chi Minh City and Ha Noi), with the Northeastern
coastal province of Quang Ninh also displaying high rates of TB, HIV
and TB/HIV co-infection. Figure 1 provides an overview of TB and
HIV notiﬁcation rates in different provinces of Vietnam duringFigure 1. Provincial TB and HIV notiﬁcation rates in Vietnam (20142014, together with the absolute number of TB/HIV co-infected
patients per province.
Figure 2 indicates the cumulative number of HIV-infected
patients over a 10-year period (2005-2014), together with the
number of patients receiving ART, the number of new HIV
infections and the number of HIV-related deaths occurring in
each year. At the end of 2014, cumulative HIV-infected cases and
HIV-related deaths were 298,151 and 71,332 respectively. Annual
HIV infections peaked in 2007 with 30,846 new cases and
decreased gradually to 11,680 cases in 2014. The annual number
of deaths attributed to HIV decreased from 7,885 to 2,146 over the
10-year period. ART coverage has been expanded and late ART
initiation (CD4 <100 cells/mm3) has been reduced from 63%
(2009) to 34.4% (2014). IPT has been made available to HIV-
infected patients in Vietnam from 2009. The cumulative number of
patients who received IPT increased from 320 in 2009 to 46,607 in
2014, accounting for 15.6% (46,607/298,151) of current HIV cases.
Vietnam National Tuberculosis Program data indicate that TB
case notiﬁcations changed little from 2011-2014, with 100,518
cases in 2011 and 102,087 cases in 2014. During that period, the
number of TB patients tested for HIV infection increased from
58.9% to 72.6% of recorded cases (Figure 3). With the increased
number of tests performed, the proportion of HIV-infected patients
among those tested declined from 8.0% in 2011 to 5.2% in
2014. Over the same time period the percentage of HIV-infected TB
patients receiving ART increased from 48.6% to 72.3% of cases.
Key characteristics of TB patients diagnosed between 2011-
2014, with and without HIV co-infection, are compared in
Table 1. Compared to HIV uninfected patients a higher percentage
of HIV co-infected TB cases were diagnosed with extra-pulmonary
TB [1,276 (28.7%) vs 12,628 (19.8%); Odds Ratio (OR) 1.6, 95%
Conﬁdence Interval (CI) 1.5–1.7]; and less were sputum smear
positive [2,245 (50.4%) vs 38,581 (60.4%); OR 0.7 (95% CI 0.6 - 0.7)].
Among sputum smear-positive TB cases, more HIV co-infected
patients presented as retreatment cases than HIV-uninfected
patients, and less as new cases [1,773 (79.0%) vs 32,827 (85.1%); OR
0.7 (95% CI 0.6–0.7)]. Most retreatment occurred after TB
recurrence [7,090/8,853 (80.1%) of retreatment cases], which
was more common among HIV-infected patients, as were
retreatment after treatment failure and treatment interruption
(Table 1). Interestingly, among MDR-TB cases a higher percentage
of HIV co-infected patients presented as new cases [6 (15.0%) vs 30
(4.0%); OR 4.2 (95% CI 1.6–10.8)] compared to HIV-uninfected
patients, although case numbers were small.), with absolute number of TB/HIV co-infected patients in care.
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Figure 2. Cumulative number of HIV-infected patients and antiretroviral therapy use in Vietnam, with number of new HIV infections and HIV-related deaths (2005–2014).
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Figure 3. Number of tuberculosis cases tested for HIV and receiving antiretroviral therapy in Vietnam (2011–2014).
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representing 0.9% of all cases. The greatest number of MDR-TB
cases occurred among treatment failures (especially category
2 failures) and patients retreated for a second TB episode (TB
recurrence). The overall percentage of TB cases with MDR disease
was less among HIV co-infected patients (40/4,452; 0.9%) than
among HIV-uninfected patients [(743/63,868; 1.2%; OR 0.77; 95%
CI 0.6–1.1)]. Figure 4 summarizes the number of patients
diagnosed with MDR-TB and enrolled for treatment, which
increased from 578 cases in 2011 to 1,532 cases in 2014. Through-
out this period the number of HIV co-infected patients among
MDR-TB cases remained low, with only 51 (3.3%) MDR-TB/HIV
co-infected patients identiﬁed in 2014.
4. Discussion
With increased HIV testing during the study period, the
proportion of HIV-infected patients among those tested declined
from 8.0% in 2011 to 5.2% in 2014.3,6,12,13 This is lower than TB/HIVco-infection rates in sub-Saharan Africa where rates in excess of
50% are reported, but similar to TB/HIV co-infection rates in India
(4%) and Cambodia (3%). Within other high TB burden countries in
Asia, TB/HIV co-infected rates in Indonesia (16%), Thailand (13%)
and Myanmar (11%) are higher, but lower in China (2%) and the
Philippines (<1%).3 However, HIV testing rates in these countries
are highly variable, with greatly reduced conﬁdence in the TB/HIV
co-infection rates reported from countries with low testing rates.
Within Vietnam the highest TB/HIV co-infection rates were
found in the two big metropolitan areas, Ho Chi Minh City and Ha
Noi. Interestingly HIV/AIDS prevalence rates were high in the
remote Northern provinces, although TB/HIV co-infection rates
were relatively low. High HIV infection rates may be a legacy of
poverty among remote tribal groups, commercial sexual exploita-
tion and movement across the Chinese border,7,14,15 while
relatively low rates of TB/HIV co-infection rates may reﬂect lower
rates of HIV testing among TB patients and reduced access to TB
and HIV services.16 The Northeastern coastal province of Quang
Ninh reported high TB, HIV and TB/HIV co-infection rates, which
Table 1
Comparison of tuberculosis patients with and without HIV co-infection in Vietnam (2011–2014)
All HIV uninfected HIV co-infected HIV status unknown OR (95% CI)*
n (%) n (%) n (%) n (%)
All TB
Pulmonary TB sm+ 59 435 (58.2) 38 581 (60.4) 2 245 (50.4) 18 609 (55.0) 0.7 (0.6 - 0.7)
Pulmonary TB sm 21 288 (20.8) 12 659 (19.8) 931 (20.9) 7 698 (22.7) 1.1 (1.0 - 1.2)
Extra-pulmonary TB 21 459 (21.0) 12 628 (19.8) 1 276 (28.7) 7 555 (22.3) 1.6 (1.5 - 1.7)
Total (N) 102 182 63 868 4 452 33 862
Pulmonary TB sm+
New 50 582 (85.1) 32 827 (85.1) 1 773 (79) 15 982 (85.9) 0.7 (0.6 - 0.7)
Retreatment after recurrence 7 090 (11.9) 4 630 (12.0) 343 (15.3) 2 117 (11.4) 1.3 (1.2 - 1.5)
Retreatment after treatment failure 573 (1.0) 394 (1.0) 37 (1.6) 142 (0.8) 1.6 (1.2 - 2.3)
Retreatment after treatment interruption 453 (0.8) 264 (0.7) 34 (1.5) 155 (0.8) 2.2 (1.6 - 3.2)
Other AFB(+) 737 (1.2) 466 (1.2) 58 (2.6) 213 (1.1) 2.2 (1.6 - 2.9)
Total (N) 59 435 38 581 2 245 18 609
MDR-TB
New 53 (5.0) 30 (4.0) 6 (15.0) 17 (9.3) 4.2 (1.6 - 10.8)
Failure Cat 1 172 (17.8) 139 (18.7) 6 (15.0) 27 (14.8) 0.8 (0.3 - 1.9)
Failure Cat 2 382 (39.6) 318 (42.8) 13 (32.5) 51 (28.0) 0.6 (0.3 - 1.3)
TB recurrence 298 (30.9) 212 (28.5) 12 (30.0) 74 (40.7) 1.1 (0.5 - 2.2)
Default 22 (2.3) 16 (2.2) 2 (5.0) 4 (2.2) 2.4 (0.5-10.8)
Other 38 (3.9) 28 (3.8) 1 (2.5) 9 (4.9) 0.7 (0.1 - 4.9)
Total (N) 965 743 40 182
sm+ = sputum smear-positive; sm = sputum smear-negative.
Cat 1 – ﬁrst-line treatment regimen (isoniazid, rifampicin, pyrazinamide, ethambutol); (2 HRZE/4 HRE).
Cat 2 – retreatment regimen; Cat 1 with added streptomycin (2 SHRZE/1 HRZE/5H3R3E3).
* OR – Odds Ratio of in HIV-infected compared to HIV-uninfected, excluding data of those with unknown HIV status.
HIV – Hu man immunod eficienc y virus;  MDR-TB  – Multidrug-resistant  tuber culosis
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Figure 4. Multidrug resistant tuberculosis cases enrolled for treatment in Vietnam and HIV co-infection status (2011–2014).
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cross-border people movement, access through its multiple
seaports and tourism related to the World Heritage status of
Halong Bay.
Despite recent progress nearly a third of TB patients did not
receive a HIV test in 2014 and of those known to be HIV-infected,
less than three quarters (73%) received ART.3 Compared to ART
provision for TB/HIV co-infected patients in other high TB burden
countries in the region Cambodia (98%), India (90%) and Myanmar
(90%) are doing better than Vietnam, but China (69%), Thailand
(69%), the Philippines (49%) and Indonesia (26%) are faring worse.3
Unfortunately many TB/HIV co-infected patients initiated on ART
were lost to follow up, especially after TB treatment conclusion.
This is a major concern and better patient support strategies are
required to ensure on-going ART beyond TB treatment completion.
We were unable to assess active TB case ﬁnding in people livingwith HIV, since this data is not reliably reported at present. Links
between the TB and HIV programmes should be strengthened to
ensure optimal bi-directional screening and long-term treatment
adherence.
To address these issues, the Government of Vietnam has issued
Guidelines for Collaboration between the National TB and HIV
programs and established a TB/HIV Coordinating body at the
central and provincial levels to implement interventions aimed at
decreasing the TB burden among people living with HIV and ensure
optimal HIV care in patients diagnosed with TB. IPT provision has
improved with nearly 50,000 HIV-infected patients receiving IPT in
2014.16 About 70–75% of TB/HIV co-infected patients received ART,
which remains well off target. It is hoped that this will improve
further since TB/HIV service delivery has now been integrated
within Provincial, District and Commune Preventive Health
Centers.
Q.M. Trinh et al. / International Journal of Infectious Diseases 46 (2016) 56–6060The total number of people living with HIV in Vietnam
continues to rise, but this is a function of improved access to
ART and increased survival rather than an excessive number of
new infections. However, everything possible should be done to
limit new HIV infections to zero. Timely ART initiation will require
outreach to key populations, integration of HIV testing into
methadone maintenance programmes and decentralized HIV
testing and care. During the study period HIV testing and
counselling services were primarily funded by international
donors. Given strong economic growth and recent recognition of
Vietnam as a middle-income country, the Government of Vietnam
needs to identify domestic funding sources to sustain and expand
HIV services into the future.17 In September 2015 the WHO
released new ART guidelines recommending ART initiation in all
HIV-infected individuals, irrespective of TB co-infection, clinical
disease stage or CD4 cell count.18 This has yet to be implemented in
Vietnam.
With assistance from the Global Fund there has been rapid
scale-up of programmatic MDR-TB management since 2009, with
more than 1,500 patients enrolled in MDR-TB treatment during
2014.16 The degree of treatment scale-up has been impressive, but
maintaining high numbers of patients on MDR-TB treatment will
require continued commitment and sustained funding. Luckily the
number of HIV-infected patients with MDR-TB remains small and
the MDR-TB epidemic is essentially independent of HIV co-
infection in Vietnam; similar to the situation in Eastern Europe,19
but in contrast to what has been observed in some sub-Saharan
African settings.20
High rates of HIV co-infection does have the potential to fuel the
MDR-TB epidemic, especially in settings with high rates of
transmitted MDR-TB.2,21 The fact that MDR-TB cases were mainly
identiﬁed among patients who failed TB treatment and among
retreatment cases may suggest that resistance acquisition is a
major contributor, but it is important to consider the strong
selection biases. Current testing protocols prioritize retreatment
cases and those who fail treatment for MDR-TB work-up. The
experience from Mongolia, Russia and South Africa suggest that
the majority of these patients likely represent transmitted MDR-
TB, even though they had previous TB treatment exposure.22–24
MDR-TB was detected with increased frequency among TB/HIV co-
infected patients that presented as new cases, which raise
additional MDR-TB transmission concerns in this group and
emphasize the need for enhanced infection control in settings
that provide joint TB and HIV services.
Some limitations of this study should be acknowledged. The
data employed in this review represent routine programmatic data
with some missing data and discordance between the TB and HIV
programmes. We were unable to conduct detailed demographic
analysis of TB patients with and without HIV co-infection or
comparisons of HIV-infected patients with and without previous
TB treatment due to lacking information. Despite these limitations,
the data sets analysed provide important real-life data and
represent the most comprehensive overview of overlapping TB
and HIV disease burdens in Vietnam, and reﬂect some objective
parameters for monitoring of integrated healthcare service
delivery performance.
In conclusion, TB/HIV co-infection is relatively uncommon
(5% of TB cases) in Vietnam and HIV infection is not a major
driver of rising MDR-TB rates. This is different to sub-Saharan
Africa and countries such as Swaziland that report TB/HIV co-
infection rates exceeding 80%, with high rates of MDR-TB among
co-infected cases.25 Irrespective of HIV co-infection rates, the
global rise of MDR-TB seems to be driven by primary transmission
of drug resistant strains.26,27 Although the cumulative number of
HIV-infected patients continues to increase in Vietnam, newHIV-infections and HIV-related deaths are on the decline.
Integrated TB/HIV services are improving, but greater effort and
more domestic funding are required to close the gap between
service delivery indicators and global targets, with special focus
on the hot-spot areas identiﬁed.
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